Bioniz Therapeutics is a private biopharmaceutical company leading the discovery and development of first-in-class anti-cytokine therapies to treat cancer and autoimmune diseases driven by unregulated T-cell biology. Bioniz leverages its world class expertise in cytokine biology to develop a pipeline of novel peptide therapeutics to selectively inhibit functionally redundant cytokines while leaving the rest of the cytokine network intact.
The company’s lead product candidate, BNZ-1, has successfully completed a Phase 1/2 clinical trial in Refractory Cutaneous T-cell lymphoma (rCTCL). Bioniz is also evaluating BNZ-1 for the treatment of autoimmune diseases, including alopecia areata and vitiligo. BNZ-2 and BNZ-3 are being developed as potential treatments for celiac disease and inflammatory bowel disease.
The company’s lead product candidate, BNZ-1, has successfully completed a Phase 1/2 clinical trial in Refractory Cutaneous T-cell lymphoma (rCTCL). Bioniz is also evaluating BNZ-1 for the treatment of autoimmune diseases, including alopecia areata and vitiligo. BNZ-2 and BNZ-3 are being developed as potential treatments for celiac disease and inflammatory bowel disease.
Location: United States, California, Irvine
Employees: 11-50
Total raised: $13M
Founded date: 2010
Investors 3
| Date | Name | Website |
| 15.09.2021 | Broadway A... | broadway-a... |
| - | Takeda Ven... | takeda.com |
| - | Cota Capit... | cotacapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.08.2016 | - | $13M | - |
Mentions in press and media 3
| Date | Title | Description |
| 19.08.2016 | OCTANe’s accelerator program shows its chops | “When a company comes through our accelerator, we can put them at different touch points for capital, whether it’s venture, private investor, strategic or potentially investing in it ourselves,” said CEO Bill Carpou. “We’ve had 208 of 210 c... |
| 01.08.2016 | Bioniz Therapeutics Raises $13M In Funding Round | Irvine-based Bioniz Therapeutics, a company developing biopharmaceuticals aimed at treating immuno-inflammatory diseases and cancer, has raised $13M in a Series A funding. The funding was co-led by Takeda Ventures and former Allergan CEO Dr... |
| - | OCTANe’s accelerator program shows its chops | Startups have a burning need to raise money; investors want the best possible returns. The trick is connecting these two groups. In Orange County, California, OCTANe is the reigning matchmaker. OCTANe was founded in 2002 to grow Orange Coun... |